The FINANCIAL — Bristol-Myers Squibb Company on December 8 announced that it has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc.
The transaction includes full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development as an intravenous treatment for acute decompensated heart failure (ADHF), according to Bristol-Myers Squibb.
Discussion about this post